Oct 29, 2019 - Is (AMGN) Outperforming Other Medical Stocks This Year?
Oct 29, 2019 - Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Oct 29, 2019 - Amgen Inc. (NASDAQ:AMGN) Q3 2019 Earnings Conference Call October 29, 2019 5:00 PM ET Company Participants Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman & Chief Executive
Oct 30, 2019 - AMGN earnings call for the period ending September 30, 2019.
Oct 31, 2019 - Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Nov 15, 2019 - Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Nov 18, 2019 - Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
Nov 19, 2019 - The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.